Victory Capital Management
CAPR icon

Victory Capital Management’s Capricor Therapeutics CAPR Stock Holding History

Victory Capital Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-685
Closed -$1K – 2623
2020
Q1 		$1K Buy
+685
New +$956 ﹤0.01% 3598
2019
Q4 		– Sell
-454
Closed -$2K – 2731
2019
Q3 		$2K Buy
+454
New +$1.57K ﹤0.01% 3616

Other funds holding CAPR

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Victory Capital Management's CAPR Position: Q2 2020 in Review

Victory Capital Management sold out of Capricor Therapeutics (CAPR) in Q2 2020, closing a stake of 685 shares — an estimated $1K sold.

Victory Capital Management first reported a position in CAPR in Q3 2019 and held it in 2 quarters. The position peaked at $2K in Q3 2019. 33 funds tracked by Wall St. Rank hold CAPR as of Q2 2020.

  • Victory Capital Management reported no remaining Capricor Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 685 Capricor Therapeutics shares in Q2 2020, an estimated $1K.
  • Victory Capital Management first reported a position in Capricor Therapeutics in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Capricor Therapeutics position peaked at $2K in Q3 2019.
  • 33 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.